Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lushang Freda Pharmaceutical CoSHSE:600223 -2.32%73 5-Year Yield-on-Cost % is 1.04 as of Aug. 23, 2026, which is 13% below its 10-year median of 1.20. GuruFocus rates SHSE:600223 with a GF Score™ of 73/100 and a GF Value™ of ¥6.59 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 858 Real Estate companies, Lushang Freda Pharmaceutical Co ranks worse than 84.85% on this metric.
The historical rank and industry rank for Lushang Freda Pharmaceutical Co's 5-Year Yield-on-Cost % or its related term are showing as below:
SHSE:600223'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.47 Med: 1.2 Max: 2.9
Current: 1.04
During the past 13 years, Lushang Freda Pharmaceutical Co's highest Yield on Cost was 2.90. The lowest was 0.47. And the median was 1.20.
SHSE:600223's 5-Year Yield-on-Cost % is ranked worse than 84.85% of 858
companies
in the Real Estate industry
Industry Median: 3.79
vs SHSE:600223: 1.04
Lushang Freda Pharmaceutical Co (SHSE:600223) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Lushang Freda Pharmaceutical Co 5-Year Yield-on-Cost % Related Terms
Lushang Freda Pharmaceutical Co 5-Year Yield-on-Cost % Competitor Comparison
For the Real Estate - Development subindustry, Lushang Freda Pharmaceutical Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lushang Freda Pharmaceutical Co 5-Year Yield-on-Cost % vs Real Estate Industry
For the Real Estate industry and Real Estate sector, Lushang Freda Pharmaceutical Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Lushang Freda Pharmaceutical Co's 5-Year Yield-on-Cost % falls into.
Lushang Freda Pharmaceutical Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Lushang Freda Pharmaceutical Co (SHSE:600223) has a 5-Year Yield-on-Cost % of 1.04 as of Aug. 23, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Lushang Freda Pharmaceutical Co and its competitors. This is 13% below median its historical median of 1.20. Over the past decade, Lushang Freda Pharmaceutical Co's 5-Year Yield-on-Cost % has ranged from 0.47 to 2.90. According to the industry distribution chart, Lushang Freda Pharmaceutical Co ranks #728 out of 858 companies in the Real Estate industry, placing it in the top 84.8%.
Is Lushang Freda Pharmaceutical Co's 5-Year Yield-on-Cost % too high?
Lushang Freda Pharmaceutical Co's current 5-Year Yield-on-Cost % of 1.04 is 13% below median its 10-year median of 1.20. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 2.90. The Real Estate industry median 5-Year Yield-on-Cost % is 3.79. Lushang Freda Pharmaceutical Co's value of 1.04 is 72.6% below this industry median. Based on the distribution chart, Lushang Freda Pharmaceutical Co ranks #728 out of 858 companies in the Real Estate industry, which is in the bottom quartile relative to peers. Overall, Lushang Freda Pharmaceutical Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lushang Freda Pharmaceutical Co's 5-Year Yield-on-Cost % compare to competitors?
According to the Real Estate industry distribution chart, Lushang Freda Pharmaceutical Co ranks #728 out of 858 companies for 5-Year Yield-on-Cost %. This places Lushang Freda Pharmaceutical Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 3.79. Lushang Freda Pharmaceutical Co's value of 1.04 is 72.6% below this benchmark. Historically, Lushang Freda Pharmaceutical Co's own 5-Year Yield-on-Cost % has ranged from 0.47 to 2.90 over the past decade. While the company's 10-year median is 1.20 vs. the industry median of 3.79, Lushang Freda Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Real Estate company?
The median 5-Year Yield-on-Cost % among Real Estate companies is 3.79, based on 858 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lushang Freda Pharmaceutical Co's current 5-Year Yield-on-Cost % of 1.04 is 72.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Lushang Freda Pharmaceutical Co and its competitors. For the Real Estate industry, the median 5-Year Yield-on-Cost % is 3.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lushang Freda Pharmaceutical Co's current 5-Year Yield-on-Cost % is 1.04, which is 13% below median its own 10-year median of 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lushang Freda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co (SHSE:600223) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥6.59, compared to a current price of ¥5.48 — trading 16.8% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.04, which is 13% below median its 10-year median of 1.20 and 72.6% below the Real Estate industry median of 3.79. Lushang Freda Pharmaceutical Co's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Lushang Freda Pharmaceutical Co (SHSE:600223), the current 5-Year Yield-on-Cost % is 1.04 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lushang Freda Pharmaceutical Co (SHSE:600223) Overvalued in 2026?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥5.48 is trading 16.8% below its estimated GF Value™ of ¥6.59.
GuruFocus considers Lushang Freda Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600223:
5-Year Yield-on-Cost %: 1.04 (13% below median its 10-year median of 1.20)
GF Value™: ¥6.59 vs. price of ¥5.48 (16.8% below fair value)
Industry Position: 72.6% below the Real Estate median (#728 of 858)
No single metric tells the full story. See the SHSE:600223 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.
73GF Score
Get the complete analysis for SHSE:600223
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600223 has been successfully added to your 
